Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The tumor suppressive role of ANCO1 in early-stage triple negative breast cancer [ChIP-seq]

ABSTRACT: The tumor suppressive role of ANCO1 in early-stage triple negative breast cancer [ChIP-seq]

PROVIDER: PRJNA957315 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24216049_1.fastq.gz	Fastqsanger.gz
	SRR24216049_2.fastq.gz	Fastqsanger.gz
	SRR24216050_1.fastq.gz	Fastqsanger.gz
	SRR24216050_2.fastq.gz	Fastqsanger.gz
	SRR24216051_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

The tumor suppressive role of ANCO1 in early-stage triple negative breast cancer

Project description:The tumor suppressive role of ANCO1 in early-stage triple negative breast cancer

| PRJNA957307 | ENA

The tumor suppressive role of ANCO1 in early-stage triple-negative breast cancer [RNA-seq]

Project description:The tumor suppressive role of ANCO1 in early-stage triple-negative breast cancer [RNA-seq]

| PRJNA957314 | ENA

The tumor suppressive role of ANCO1 in early-stage triple-negative breast cancer [RNA-seq]

Project description:To understand the impact of ANCO1 reduction on gene expressions, we performed RNA-seq experiments in shANCO1 and shCTRL MCF10A and MCFDCIS cells in 2D and 3D culture. We report ANCO1 knockdown leads to altered gene expression profiles. Enriched gene sets including chr1q21.3 and mTORC1 signaling may be responsible for phenotypical changes in shANCO1 cell lines.

2023-07-31 | GSE230062 | GEO

The tumor suppressive role of ANCO1 in early-stage triple negative breast cancer [ChIP-seq]

Project description:To examine the impact of ANCO1 reduction on H3K27Ac modification and its association with gene expression changes, we performed ChIP-seq experiments in shANCO1 and control MCF10A and MCFDCIS cells. We report ANCO1 knockdown causes global changes to H3K27Ac pattern and enhances accessibility of breast cancer enhancers. Altered H3K27Ac signal is associated with gene expression changes.

2023-07-31 | GSE230061 | GEO

The tumor suppressive role of ANCO1 in early-stage triple negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-07-31 | GSE230063 | GEO

Anti-Neoplastic Activity of Estrogen Receptor Beta in Chemoresistant Triple-Negative Breast Cancer

Project description:The standard of care for triple-negative breast cancer is chemotherapy followed by surgical resection, and in most cases, additional rounds of chemotherapy treatment. While highly effective, approximately half of patients will experience disease recurrence that does not respond to additional rounds of treatment. Previous findings demonstrate that estrogen receptor beta (ERb) is expressed in upwards of 20% of triple-negative tumors, and that ERb functions as a tumor suppressor in triple-negative breast cancer models, it was of interest to determine if the tumor-suppressive effects of ERb persisted in chemo-therapy-resistant forms of the disease. Here, we demonstrate that the activation of ERb in chemotherapy-resistant triple-negative breast cancer cell lines elicits equivalent or superior inhibitory effects compared to chemotherapy-sensitive counterparts. These findings support the potential use of ERb-targeting agents in advanced forms of the disease.

2025-07-01 | GSE300447 | GEO

Triple therapy reduced metastasis in triple-negative breast cancer

Project description:Triple therapy reduced metastasis in triple-negative breast cancer

| PRJNA857888 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

Sulindac sulfide as a non-immune suppressive gamma-secretase modulator to target Triple-Negative Breast Cancer

Project description:Sulindac sulfide as a non-immune suppressive gamma-secretase modulator to target Triple-Negative Breast Cancer

| PRJNA1006333 | ENA

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data